Sun Pharma appoints Kirti Ganorkar as the Managing Director

Dilip Shanghvi to continue as the Executive Chairman of the Board

Sun Pharma gets FDA approval for new device to treat skin disease

Sun Pharmaceutical receives USFDA approval for oral JAK inhibitor ‘Leqselvi’

Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials

Sun Pharma and Moebius Medical present Phase 2b study on MM-II

There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis

Sun Pharma gets USFDA filing acceptance of new drug application for Deuruxolitinib

The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials

Sun Pharma Canada launches Prwinlevi for treatment for acne

WINLEVI works differently from any other topical acne treatment

Sun Pharma completes acquisition of Concert Pharmaceuticals

The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market

Sun Pharma launches SEZABY in the US for treatment of neonatal seizures

SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection

Sun Pharma launches ophthalmic solution in Canada

CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration

Sun Pharma's Winlevi available in the US

It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years